Filing Flows › TG Therapeutics (TGTX) › Guidance & outlook
TG Therapeutics (TGTX) guidance and outlook
TG Therapeutics (TGTX) raised its guidance on Nov 9, 2026: Revenue (segment) $1.0B for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.0B | raised |
From the earnings release filed Nov 9, 2026 (8-K on EDGAR).
TG Therapeutics' latest quarter
TG Therapeutics, Q3 2026: revenue $260M (+61% year over year), operating margin 33.0%, net earnings $55.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did TG Therapeutics raise or lower its guidance?
TG Therapeutics (TGTX) raised its guidance on Nov 9, 2026: Revenue (segment) $1.0B for FY2026.
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.